A recent study suggests that patients who discontinue blockbuster weight-loss injections like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who stop traditional lifestyle regimens.
Research printed in a major medical journal demonstrates that while obese people can lose a large proportion of their total mass while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"Individuals purchasing these medications must be aware of the danger of quick weight regain when the treatment ends," cautioned researcher Dr. Susan Jebb.
Such speed of regain implies a reversion to starting weight in about a year and a half.
Comparing Treatments
The analysis, which examined dozens of studies involving over 9,000 of patients, compared the effects of the injectable medications with older methods.
Researchers note that people who lose weight through dieting usually have a more gradual creep back—perhaps 100 grams monthly—once they finish.
The Reason for the Rapid Rebound
Doctors suggest the way of the drugs is key to understanding the heightened rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which moderates hunger.
"Sustained high doses of GLP-1 levels far above than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and could diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement results in hunger is unsuppressed, making excessive eating far more likely."
A Chronic Disease?
Health authorities advise the injections for people with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians say that, due to the likelihood of relapse, the therapy might need to be life-long.
This opinion is supported by drug manufacturers, who note that the results "emphasize the chronic character of excess weight," similar to managing conditions like high blood pressure.
Patient Experiences
Users who have stopped the medication explain a powerful resurgence of cravings.
"It felt as if a trigger that goes on and you're instantly starving," said an individual.
This challenge is compounded if users have not developed sustainable dietary or behavioural changes during therapy.
Significant Interest
Figures indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Use is more common among females than men.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private healthcare rather than public health services.
Finally, clinicians stress that while the jabs are effective tools for weight loss, they are not a magic fix and lasting health benefits relies on combined behavioural changes.
